"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved cabozantinib (Cabometyz; Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.
Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451
Waltham, MA. 02451